Opendata, web and dolomites

REGHA

Medical device combining viscosupplementation with pharmacological active molecule to regenerate cartilage in degenerative or traumatic osteoarthritis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 REGHA project word cloud

Explore the words cloud of the REGHA project. It provides you a very rough idea of what is the project "REGHA" about.

active    adults    positive    injuries    burden    regenerative    innovation    blood    market    device    people    subsequent    breakthrough    worldwide    osteoarthritis    molecules    found    surgery    frequent    local    therapeutic    injectable    million    phases    completion    social    validation    solution    proliferation    economic    molecule    roi    plan    viscosupplementation    innovative    cheaper    clinical    batch    concerning    maintaining    15    degree    population    injection    join    formulation    cells    10    easily    commercialization    cartilage    biological    medical    degenerative    refined    disease    combining    vessels    planning    glp    health    packaging    treatment    globally    joint    matrix    stimulating    unmet    business    degeneration    md    commercialize    manufacturing    patented    aging    producing    altogether    affordable    combined    administered    oa    pharmacological    therapy    locally    feasibility    undertaken    strategy    huge    final    commercial    production    highest    contain    combination    chondrocytes   

Project "REGHA" data sheet

The following table provides information about the project.

Coordinator
REGULAXIS 

Organization address
address: 102 AVENUE GASTON ROUSSEL
city: ROMAINVILLE
postcode: 93230
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.regulaxis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGULAXIS FR (ROMAINVILLE) coordinator 50˙000.00

Map

 Project objective

To develop and commercialize a medical device (MD) that can effectively respond to unmet therapeutic needs in the treatment of osteoarthritis (OA), namely degeneration of cartilage. OA is a huge medical, social and economic burden worldwide. This therapeutic approach by local injection in the join will be a breakthrough innovation for OA therapy. The expected product is a combination of HA viscosupplementation with our pharmacological active patented molecule stimulating chondrocytes proliferation, the only cells producing and maintaining the cartilage matrix. Cartilage does not contain blood vessels, therefore this requires the product be administered locally. Our innovative project will provide a MD allowing an easily, affordable and cheaper solution than surgery for the therapeutic treatment of OA and should have a positive impact on the economic and social cost of OA. The commercial potential is one of the highest in the field of health because there are currently no specific therapeutic molecules on the market for this frequent degenerative disease. Users are to be found in the aging population and people with joint injuries in need for a regenerative therapy. The feasibility assessment undertaken in Phase I will be the completion of the technical feasibility studies for combining our molecule with HA in an injectable solution, for formulation and production of the combined products including validation of its biological activities and the selection of manufacturing partners for the MD final production (processes for production of the final GLP batch and packaging will be assessed) allowing the subsequent planning & implementation of manufacturing for clinical phases. The commercialization plan will be refined using detail analysis of potential users, ROI for the different business cases and the best strategy for commercialization In Europe altogether 10%-15% of adults over 60 have some degree of OA globally estimated concerning more than 70 million of people.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REGHA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REGHA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More